Related Experiment Video

Updated: Jun 6, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

[Target therapy of gefitinib in advanced adenocarcinoma of the lung]

Hua Zheng1, Jingping Wang, Qiyi Meng

  • 1General Department, Beijing Thoracic Tumor and Tuberculosis Hospital, Beijing 101149, P.R.China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|December 2, 2010
PubMed
Abstract

Insights

Gefitinib effectively treats advanced lung adenocarcinoma, improving survival and quality of life with manageable side effects. Key prognostic factors for longer survival include younger age, skin rash, and decreased CEA levels.

Area of Science:

  • Oncology
  • Pharmacology

Context:

  • Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
  • It is used for advanced non-small cell lung cancer, particularly adenocarcinoma.

Purpose:

  • Evaluate the efficacy of gefitinib in lung adenocarcinoma.
  • Assess side effects and identify prognostic factors for gefitinib treatment.

Summary:

  • A study of 26 patients with advanced lung adenocarcinoma showed an objective response rate of 46.2% and a disease control rate of 80.8% with gefitinib.
  • Median progression-free survival was 8.2 months, and median overall survival was 10.4 months.
  • Younger age, skin rash, and decreased CEA levels were associated with improved survival.

Impact:

  • Gefitinib demonstrates effectiveness as a targeted therapy for lung adenocarcinoma.
  • It offers a viable treatment option with mild side effects, improving patient quality of life.
  • Gefitinib can be considered first-line therapy for patients unsuitable for chemotherapy.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...